Structural flaws are hiding in plain sight, and a shift is long overdue, writes Pujitha Gourabathini at Becton, Dickinson and ...
MammaPrint effectively predicts chemotherapy benefit and distant recurrence-free interval in HR+HER2- early breast cancer. High-risk patients benefit significantly from chemotherapy, while low-risk ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results